Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 358Carcinoma, Non-Small-Cell Lung 178Neoplasms 109Breast Neoplasms 97Lung Neoplasms 81Urinary Bladder Neoplasms 79Neoplasm Metastasis 74Ovarian Neoplasms 53Cholangiocarcinoma 39Sarcoma 38Lymphoma 38Biliary Tract Neoplasms 35Gallbladder Neoplasms 34Hodgkin Disease 30Lymphoma, Non-Hodgkin 27Adenocarcinoma 27Lymphoma, Large B-Cell, Diffuse 25Colorectal Neoplasms 24Bile Duct Neoplasms 23Triple Negative Breast Neoplasms 22Recurrence 22Fallopian Tube Neoplasms 22Unspecified Adult Solid Tumor, Protocol Specific 21Carcinoma, Transitional Cell 21Carcinoma, Ovarian Epithelial 21Urethral Neoplasms 20Carcinoma 17Adenocarcinoma of Lung 15Head and Neck Neoplasms 14Carcinoma, Renal Cell 14

Interventions

Oxaliplatin 1Gemcitabine 1Electroporation 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Unresectable Pancreatic Cancer × Gemcitabine × Clear all
NCT02035072 2017-07-21

Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed
40 enrolled
Gastrointestinal

Unresectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡